Table III.

Reactivity of PBMCs from patients immunized with 209-2M peptide in IFAa

PatientBefore ImmunizationAfter ImmunizationClinical Response
IVSbNo pepc209-paFold incdIVSNo pep209-paFold inc
a(−)1181010.9(+)1317155.5NRe
b(−)3162450.8(+)14210,89376.7NR
c(−)1031071.0(+)675468.1NR
d(−)38741.9(+)504018.0NR
e(−)4713020.6(+)6001,2592.1NR
f(−)73690.9(−)1101481.3NR
g(−)4723230.7(−)941771.9NR
h(−)65520.8(−)58701.2NR
i(−)47400.9(+)59581.0NR
j(−)52611.2(+)71771.1NR
  • a Data refer to the first retrospective pilot study in which IVS results were compared with direct reactivity in PBMC using real time quantitative RT-PCR. Preimmunization samples were obtained 1–3 days before administration of the first vaccination. Postimmunization samples were obtained 3–4 wk after the second vaccination.

  • b PBMCs incubated with 209-2M for 11–13 days before assay against T2 cells alone or pulsed with 209-pa peptide (1 μg/ml). (+), 209-pa reactivity with IFN-γ release (ELISA) that is >100 pg IFN-γ/ml and at least twice that of controls. (−), 209-pa reactivity less than twice that of controls.

  • c Direct quantitative PCR assay. Fresh PBMC were incubated for 2 h with no peptide (No pep) or 209-pa (1 mg/ml). Values represent copies of IFN-γ mRNA per 104 copies of CD8 mRNA. 209-pa reactivity twice control (No pep) are underlined.

  • d Fold increase (inc), 209-pa values divided by No pep values. Fold increase ≥2 are underlined.

  • e NR, no response.